Novel integrase inhibitors for HIV

Bibliography

• Mocroft A, Vella S, Benfield TL, Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352(9142):1725-30
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-60
   PubMed Web of Science ®Google Scholar
• Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005;4(3):236-48
   PubMed Web of Science ®Google Scholar
• Wilkinson TA, Januszyk K, Phillips ML, Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. J Biol Chem 2009;284(12):7931-9
   PubMed Web of Science ®Google Scholar
• Wu X, Liu H, Xiao H, Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol 1999;73(3):2126-35
   PubMed Web of Science ®Google Scholar
• Zhu K, Dobard C, Chow SA. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 2004;78(10):5045-55
   PubMed Web of Science ®Google Scholar
• Dobard CW, Briones MS, Chow SA. Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription. J Virol 2007;81(18):10037-46
   PubMed Web of Science ®Google Scholar
• Lu R, Ghory HZ, Engelman A. Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase. J Virol 2005;79(16):10356-68
   PubMed Web of Science ®Google Scholar
• Shun MC, Raghavendra NK, Vandegraaff N, LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev 2007;21(14):1767-78
   PubMed Web of Science ®Google Scholar
• Marshall HM, Ronen K, Berry C, Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One 2007;2(12):e1340
   PubMed Web of Science ®Google Scholar
• Deprez E, Tauc P, Leh H, DNA binding induces dissociation of the multimeric form of HIV-1 integrase: a time-resolved fluorescence anisotropy study. Proc Natl Acad Sci USA 2001;98(18):10090-5
   PubMed Web of Science ®Google Scholar
• Guiot E, Carayon K, Delelis O, Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J Biol Chem 2006;281(32):22707-19
   PubMed Web of Science ®Google Scholar
• Faure A, Calmels C, Desjobert C, HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res 2005;33(3):977-86
   PubMed Web of Science ®Google Scholar
• Li M, Mizuuchi M, Burke TR Jr, Retroviral DNA integration: reaction pathway and critical intermediates. EMBO J 2006;25(6):1295-304
   PubMed Web of Science ®Google Scholar
• Brady T, Agosto LM, Malani N, HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 2009;23(12):1461-71
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Felock P, Witmer M, Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287(5453):646-50
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Young SD, Guare JP, Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004;305(5683):528-32
   PubMed Web of Science ®Google Scholar
• Hare S, Gupta SS, Valkov E, Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010
   Google Scholar
• Marchand C, Maddali K, Metifiot M, HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem 2009;9(11):1016-37
   PubMed Web of Science ®Google Scholar
• Ramkumar K, Serrao E, Odde S, HIV-1 integrase inhibitors: 2007-2008 update. Med Res Rev 2010
   Google Scholar
• Markowitz M, Morales-Ramirez JO, Nguyen BY, Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006;43(5):509-15
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009;52(3):350-6
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46(2):125-33
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Nguyen B-Y, Markowitz M, Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment-naive HIV-1-infected Patients [Poster 514]. 17th CROI; San Francisco, 16 – 19 February 2010
   Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374(9692):796-806
   PubMed Web of Science ®Google Scholar
• Lennox J, DeJesus E, Lazzarin A, Raltegravir demonstrates durable efficacy through 96 weeks: results from STARTMRK, a phase III study of raltegravir (RAL)-based vs efavirenz (EFV)-based combination therapy in treatment-naive HIV-infected patients [Poster H924b]. 49th ICAAC; San Francisco, 12 – 15 September 2009
   Google Scholar
• Murray JM, Emery S, Kelleher AD, Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007;21(17):2315-21
   PubMed Web of Science ®Google Scholar
• Sedaghat AR, Dinoso JB, Shen L, Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 2008;105(12):4832-7
   PubMed Web of Science ®Google Scholar
• Donahue D, Sloan R, Kuhl B, Stage-dependent Inhibition of HIV-1 in vitro and Implications for Raltegravir [Poster 262]. 17th CROI; San Francisco, 16 – 19 February 2010
   Google Scholar
• Sedaghat AR, Siliciano RF, Wilke CO. Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antivir Ther 2009;14(2):263-71
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, Nguyen BY, Katlama C, Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369(9569):1261-9
   PubMed Web of Science ®Google Scholar
• Gatell J, Katlama C, Grinsztejn B, Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II Study. J Acquir Immune Defic Syndr 2010;53(4):456-63
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359(4):339-54
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359(4):355-65
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Teppler H, Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010;50(4):605-12
   PubMed Web of Science ®Google Scholar
• Eron J, Cooper D, Steigbigel RT, Sustained antiretroviral effect of raltegravir at week 156 in the BENCHMRK Studies and exploratory analysis of late outcomes based on early virologic responses [Poster 515]. 17th CROI; San Francisco, 16 – 19 February 2010
   Google Scholar
• Eron JJ, Young B, Cooper DA, Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375(9712):396-407
   PubMed Web of Science ®Google Scholar
• Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008;22(10):1224-6
   PubMed Web of Science ®Google Scholar
• De Castro N, Braun J, Charreau I, Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009;49(8):1259-67
   PubMed Web of Science ®Google Scholar
• Scherrer AU, von Wyl V, Fux CA, Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. J Acquir Immune Defic Syndr 2010;53(4):464-71
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc.: ISENTRESS prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022145s004lbl.pdf. [Date of access: 29 June 2010]
   Google Scholar
• Charpentier C, Karmochkine M, Laureillard D, Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008;9(9):765-70
   PubMed Web of Science ®Google Scholar
• Fransen S, Gupta S, Danovich R, Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009;83(22):11440-6
   PubMed Web of Science ®Google Scholar
• Fransen S, Karmochkine M, Huang W, Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother 2009;53(10):4522-4
   PubMed Web of Science ®Google Scholar
• Malet I, Delelis O, Soulie C, Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 2009;63(4):795-804
   PubMed Web of Science ®Google Scholar
• da Silva D, Van Wesenbeeck L, Breilh D, HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010;65(6):1262-9
   PubMed Web of Science ®Google Scholar
• Delelis O, Malet I, Na L, The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 2009;37(4):1193-201
   PubMed Web of Science ®Google Scholar
• Canducci F, Sampaolo M, Marinozzi MC, Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009;23(4):455-60
   PubMed Web of Science ®Google Scholar
• Ferns RB, Kirk S, Bennett J, The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 2009;23(16):2159-64
   PubMed Web of Science ®Google Scholar
• Buzon MJ, Dalmau J, Puertas MC, The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS 2010;24(1):17-25
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Lyseng-Williamson KA, Perry CM. Raltegravir. Drugs 2008;68(1):131-8
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Keam SJ. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 2009;69(8):1059-75
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Petry AS, Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008;83(2):293-9
   PubMed Web of Science ®Google Scholar
• Kassahun K, McIntosh I, Cui D, Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007;35(9):1657-63
   PubMed Web of Science ®Google Scholar
• Wenning LA, Hanley WD, Brainard DM, Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009;53(7):2852-6
   PubMed Web of Science ®Google Scholar
• A study to determine the safety and efficacy of once daily raltegravir compared to twice daily raltegravir. ClinicalTrials.gov identifier: NCT00745823. Available from: http://clinicaltrials.gov/ct2/show/NCT00745823?term=NCT00745823&rank=1
   Google Scholar
• Marinello J, Marchand C, Mott BT, Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008;47(36):9345-54
   PubMed Web of Science ®Google Scholar
• Shimura K, Kodama E, Sakagami Y, Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008;82(2):764-74
   PubMed Web of Science ®Google Scholar
• Roquebert B, Damond F, Collin G, HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008;62(5):914-20
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. Ann Pharmacother 2010;44(1):145-56
   PubMed Web of Science ®Google Scholar
• DeJesus E, Berger D, Markowitz M, Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43(1):1-5
   PubMed Web of Science ®Google Scholar
• Mathias AA, West S, Hui J, Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009;85(1):64-70
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Kakuda TN, Mack R, Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antivir Ther 2008;13(8):1011-17
   PubMed Web of Science ®Google Scholar
• Goethals O, Clayton R, Van Ginderen M, Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008;82(21):10366-74
   PubMed Web of Science ®Google Scholar
• Garvey EP, Johns BA, Gartland MJ, The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother 2008;52(3):901-8
   PubMed Web of Science ®Google Scholar
• McColl DJ, Fransen S, Gupta S, Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase 2 Study of elvitegravir (GS-9137) [Abstract 9]. XVI International Drug Resistance Workshop; Barbados, Bridgetown, 12 – 16 June 2007
   Google Scholar
• Low A, Prada N, Topper M, Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 2009;53(10):4275-82
   PubMed Web of Science ®Google Scholar
• Van Baelen K, Van Eygen V, Rondelez E, Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 2008;22(14):1877-80
   PubMed Web of Science ®Google Scholar
• Zolopa AR, Berger DS, Lampiris H, Activity of Elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010;201(6):814-22
   PubMed Web of Science ®Google Scholar
• Multicenter, randomized, double-blind, double-dummy, Phase 3 study of the safety and efficacy of ritonavir-boosted elvitegravir (EVG/r) versus raltegravir (RAL). ClinicalTrials.gov identifier: NCT00708162. Available from: http://clinicaltrials.gov/ct2/show/NCT00708162?term=elvitegravir&rank=4
   Google Scholar
• Safety and efficacy of GS-9350-boosted atazanavir compared to ritonavir-boosted atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV-1 infected, antiretroviral treatment-naive adults. ClinicalTrials.gov identifier: NCT00892437. Available from: http://clinicaltrials.gov/ct2/show/NCT00892437?term=GS-9350&rank=1
   Google Scholar
• Cohen C, Shamblaw D, Ruane P, Single-tablet, fixed-dose regimen of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster [Poster 58LB]. 17th CROI; San Francisco, 16 – 19 February 2010
   Google Scholar
• Sato A, Kobayashi M, Yoshinaga T, S/GSK1349572 is a potent next generation HIV integrase inhibitor 5th IAS; Cape Town, 19 – 22 July 2009
   Google Scholar
• Underwood M, Johns B, Sato A, S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy [Poster WePeA098]. 5th IAS; Cape Town, 19 – 22 July 2009
   Google Scholar
• Seki T, Kobayashi M, Wakasa-Morimoto C, S/GSK1349572 Is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones [Poster 555]. 17th CROI; San Francisco, 16 – 19 February 2010
   Google Scholar
• Min S, Song I, Borland J, Pharmacokinetic (PK) and safety in healthy subjects of S/GSK1349572, a next generation, once-daily HIV integrase inhibitor (INI). 5th IAS; Cape Town, 19 – 22 July 2009
   Google Scholar
• Min S, Song I, Borland J, Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers [Poster A1-1303]. Antimicrob Agents Chemother; 54(1):254-8
   PubMed Web of Science ®Google Scholar
• Song I, Min S, Borland J, Lack of interaction between the HIV integrase inhibitor, S/GSK1349572, and tenofovir disoproxil fumarate (TDF) in healthy subjects [Poster 616]. 49th ICAAC, 12 – 15 September 2009
   Google Scholar
• Song I, Borland J, Chen S, Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next generation integrase inhibitor, S/GSK1349572. 17th CROI; San Francisco, 16 – 19 February 2010
   Google Scholar
• Song I, Patel A, Min S, Evaluation of antacid and multivitamin (MVI) effects on S/GSK1349572 pharmacokinetics (PK) in healthy subjects [Poster A1-1305]. 49th ICAAC; San Francisco, 12 – 15 September 2009
   Google Scholar
• Lalezari J, Sloan L, DeJesus E, Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-Naive HIV-1-infected patients: ING111521 protocol. 5th IAS. Cape Town, 19 – 22 July 2009. Abstract TUAB105
   Google Scholar
• Song I, Chen S, Lou Y, Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572, a next generation integrase inhibitor (INI), in HIV-a infected patients [Poster WePeB250]. 5th IAS. Cape Town, 19 – 22 July 2009
   Google Scholar
• A dose ranging trial of GSK1349572 and 2 NRTI in HIV-1 infected, therapy naive subjects (ING112276). ClinicalTrials.gov identifier: NCT00951015. Available from: http://clinicaltrials.gov/ct2/show/NCT00951015
   Google Scholar
• A clinical research study for assessing the effectiveness of the new integrase inhibitor GSK1349572 in HIV-infected persons with prior antiretroviral treatment and resistance to raltegravir. ClinicalTrials.gov identifier: NCT00950859. Available from: http://clinicaltrials.gov/ct2/show/NCT00950859
   Google Scholar
• Min S, DeJesus E, McCurdy L, Pharmacokinetics (PK) and safety in healthy and HIV-infected subjects and short-term antiviral efficacy of S/GSK1265744, a next generation once daily HIV integrase inhibitor [Poster H-1228]. 49th ICAAC; San Francisco, 12 – 15 September 2009
   Google Scholar
• Ceccherini-Silberstein F, Malet I, D'Arrigo R, Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009;11(1):17-29
   PubMed Web of Science ®Google Scholar
• Ge H, Si Y, Roeder RG. Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J 1998;17(22):6723-9
   PubMed Web of Science ®Google Scholar
• Singh DP, Fatma N, Kimura A, LEDGF binds to heat shock and stress-related element to activate the expression of stress-related genes. Biochem Biophys Res Commun 2001;283(4):943-55
   PubMed Web of Science ®Google Scholar
• Fatma N, Singh DP, Shinohara T, Transcriptional regulation of the antioxidant protein 2 gene, a thiol-specific antioxidant, by lens epithelium-derived growth factor to protect cells from oxidative stress. J Biol Chem 2001;276(52):48899-907
   PubMed Web of Science ®Google Scholar
• Maertens GN, Cherepanov P, Engelman A. Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J Cell Sci 2006;119(Pt 12):2563-71
   PubMed Web of Science ®Google Scholar
• Ciuffi A, Llano M, Poeschla E, A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med 2005;11(12):1287-9
   PubMed Web of Science ®Google Scholar
• Meehan AM, Saenz DT, Morrison JH, LEDGF/p75 proteins with alternative chromatin tethers are functional HIV-1 cofactors. PLoS Pathog 2009;5(7):e1000522
   PubMed Web of Science ®Google Scholar
• Ronen K, Gijsbers R, Vets S, Use of LEDGF/p75 Fusion proteins to retarget lentiviral integration outside of genes [Poster 145]. 17th CROI; San Francisco, 16 – 19 February 2010
   Google Scholar
• Llano M, Saenz DT, Meehan A, An essential role for LEDGF/p75 in HIV integration. Science 2006;314(5798):461-4
   PubMed Web of Science ®Google Scholar
• Vandekerckhove L, Christ F, Van Maele B, Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol 2006;80(4):1886-96
   PubMed Web of Science ®Google Scholar
• De Rijck J, Vandekerckhove L, Gijsbers R, Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol 2006;80(23):11498-509
   PubMed Web of Science ®Google Scholar
• Llano M, Delgado S, Vanegas M, Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase. J Biol Chem 2004;279(53):55570-7
   PubMed Web of Science ®Google Scholar
• Sutherland HG, Newton K, Brownstein DG, Disruption of Ledgf/Psip1 results in perinatal mortality and homeotic skeletal transformations. Mol Cell Biol 2006;26(19):7201-10
   PubMed Web of Science ®Google Scholar
• Hombrouck A, De Rijck J, Hendrix J, Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog 2007;3(3):e47
   PubMed Web of Science ®Google Scholar
• Benarous R, Barbey S, Simon A, Identification of anti-retroviral compounds active on viruses resistant to raltegravir and that inhibit HIV-1 integration despite the absence of effect on the catalytic activity of integrase [Poster 555]. 16th CROI; Montreal, 8 – 11 February 2009
   Google Scholar
• Debyser Z. Cellular co-factors of HIV integrase: from target identification to drug discovery. 16th CROI; Montreal, 8 – 11 February 2009
   Google Scholar
• Christ F, Langedijk H, Bartholomeeussen K, Novel treatment strategies in HIV-1 drug discovery: targeting the HIV-1 integrase-LEDGF/p75 interaction. 16th CROI; Montreal, 8 – 11 February 2009
   Google Scholar
• De Luca L, Barreca ML, Ferro S, Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem 2009;4(8):1311-16
   PubMed Web of Science ®Google Scholar
• Christ F, Voet A, Marchand A, First-in-class inhibitors of LEDGF/p75-integrase interaction and HIV replication. 17th CROI; San Francisco, 16 – 19 February 2010
   Google Scholar
• Christ F, Voet A, Marchand A, Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010;6(6):442-8
   PubMed Web of Science ®Google Scholar
• The DHHS Panel on antiretroviral guidelines for adults and adolescents – a Working Group of the Office of AIDS Research Advisory Council (OARAC): guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf [Date of access: 29 June 2010]
   Google Scholar